Close this search box.

CFOs depart Vir, Cellectis

ARTICLE | Management Tracks

Plus: Lykos names CCO, VP, and an update from Iktos

By Richard Guy, Biopharma Analyst, and Gunjan Ohri, Data Content Analyst  

May 4, 2024 1:00 AM UTC

Vir Biotechnology Inc. (NASDAQ:VIR) and Cellectis S.A. (Euronext:ALCLS; NASDAQ:CLLS) both announced CFO changes. EVP and CFO Sung Lee left Vir on May 2 to pursue another career opportunity, and CFO Bing Wang resigned from Cellectis, effective the same day. Vir has initiated a search for a successor to Lee. Cellectis named CBO Arthur Stril, who joined the company in 2018 as VP, corporate development, as interim CFO. 

Lykos Therapeutics PBC hired Allison Rosenthal as chief commercial officer, as the company prepares to launch midomafetamine capsules. Rosenthal was head of the U.S. neuroscience sales and marketing at Otsuka Holdings Co. Ltd. (Tokyo:4578). Lykos also hired Coy Stout as VP of market access…